David M Mott has bought stock on 45 days since Jan 2016
Director at Ardelyx, Inc., and 15 other companies
SEC CIK 0001219871 · Filings on SEC.gov ↗
David M Mott's record
3 months after each buy, from the first price a copier could get.
9 buys since 2016 with 3 months of prices.
Companies
- ARDX Ardelyx, Inc.Director
- IMRA Bitwise MARA Option Income Strategy ETFDirector
- NVAX Novavax, Inc.Director
- EPZM Epizyme, Inc.Director
- ADAP Adaptimmune Therapeutics PlcDirector and 10% owner
- TRVI Trevi Therapeutics, Inc.10% owner
- RGLS Regulus Therapeutics Inc.10% owner
- AVEO Aveo Pharmaceuticals, Inc.10% owner
- MRSN Mersana Therapeutics, Inc.Director and 10% owner
- SURF Surface Oncology, Inc.10% owner
- TCON Tracon Pharmaceuticals, Inc.10% owner
- TSRO Tesaro, Inc.Director and 10% owner
- ABIO Arca Biopharma, Inc.10% owner
- APPN Appian Corporation10% owner
- RYTM Rhythm Pharmaceuticals, Inc.10% owner
- ILIU Interleukin Genetics Inc10% owner
Every filing
51 filings since Jan 2016, newest first
Ardelyx, Inc.
Director
Ardelyx, Inc.
Director
Ardelyx, Inc.
Director
Ardelyx, Inc.
Director
Ardelyx, Inc.
Director
Ardelyx, Inc.
Director
Ardelyx, Inc.
Director
Ardelyx, Inc.
Director
Ardelyx, Inc.
Director
Imara Inc.
Director
Imara Inc.
Director
Imara Inc.
Director
Novavax Inc
Director
Epizyme, Inc.
Director
Ardelyx, Inc.
Director
Adaptimmune Therapeutics Plc
Director and 10% owner
Epizyme, Inc.
Director
Epizyme, Inc.
Director
Trevi Therapeutics, Inc.
10% owner
Regulus Therapeutics Inc.
10% owner
Aveo Pharmaceuticals Inc
10% owner
Mersana Therapeutics, Inc.
Director and 10% owner
Aveo Pharmaceuticals Inc
10% owner
Aveo Pharmaceuticals Inc
10% owner
Aveo Pharmaceuticals Inc
10% owner
Aveo Pharmaceuticals Inc
10% owner
Aveo Pharmaceuticals Inc
10% owner
Aveo Pharmaceuticals Inc
10% owner
Epizyme, Inc.
Director
Adaptimmune Therapeutics Plc
Director and 10% owner
Aveo Pharmaceuticals Inc
10% owner
Aveo Pharmaceuticals Inc
10% owner
Aveo Pharmaceuticals Inc
10% owner
Surface Oncology, Inc.
10% owner
Aveo Pharmaceuticals Inc
10% owner
Adaptimmune Therapeutics Plc
Director and 10% owner
Tracon Pharmaceuticals, Inc.
10% owner
Adaptimmune Therapeutics Plc
Director and 10% owner
Tesaro, Inc.
Director and 10% owner
Arca Biopharma, Inc.
10% owner
Appian Corp
10% owner
Appian Corp
10% owner
Rhythm Pharmaceuticals, Inc.
10% owner
Epizyme, Inc.
Director
Mersana Therapeutics, Inc.
Director and 10% owner
Aveo Pharmaceuticals Inc
10% owner
Adaptimmune Therapeutics Plc
Director and 10% owner
Interleukin Genetics Inc
10% owner
Ardelyx, Inc.
Director and 10% owner
Ardelyx, Inc.
Director and 10% owner
About David M Mott
David M. Mott is a seasoned biotechnology executive and investor serving as Chairman of the Board of Directors at Ardelyx, Inc. (ARDX) since March 2014, having joined the board in March 2009.( Currently a private investor through Mott Family Capital, he holds chair positions at Mersana Therapeutics and Cydan LLC, and serves on the board of Novavax, Inc., previously chairing Adaptimmune Therapeutics until 2025.(
Mott's career highlights include leading MedImmune as President and CEO from 2000 to 2008, orchestrating its $15.6 billion acquisition by AstraZeneca in 2007, after roles as CFO and COO since joining in 1992; he also founded MedImmune Ventures in 2002.( From 2008 to 2020, he was a General Partner at New Enterprise Associates (NEA), heading healthcare investments and contributing to over $40 billion in deals and 35+ IPOs/acquisitions.( Earlier, he was Vice President in healthcare investment banking at Smith Barney.( He holds a B.A. in Economics and Government from Dartmouth College.(
Written by Perplexity from public sources.
Filings come from SEC EDGAR. Not investment advice.